Table 2 Medications, treatment subjects and blood pressure control of included studies with 6-month follow-up.

Schirmer

4.3 ± 0.1

66(100)

Patients scheduled for RDN for treatment of resistant hypertension (defined as office systolic blood pressure [SBP] >140 mm Hg)

−21.6*

Ewen

5.0 ± 1.6

23(92)

Patients with resistant hypertension (office SBP of at least 140 mmHg despite treatment with three or more antihypertensive drugs of different classes, including a diuretic at the maximum or highest tolerated dose)

−10*

Berukstis

6.44 ± 0.96

16(100)

Patients with suspected resistant hypertension

−16.2

Dorr

5.2 ± 1.2

99(99)

Patients with at least three antihypertensive medications of different classes, including diuretics, at the maximum tolerated doses and with office SBP >160 mm Hg (>150 mm Hg, type 2 diabetes mellitus) or ABPM > 135 mm Hg.

−11.4*

Ripp

NR

NR

Patients with blood pressure over 160/100 mmHg, and administration of at least three antihypertensive drugs in full doses plus a diuretic.

−11.1

Dores

5.8 ± 1.0

NR

With resistant hypertension

−5

McLellan

4.9 ± 1.8

14(100)

patients with treatment-resistant hypertension (defined as BP greater than goal target despite concurrent use of at least 3 antihypertensive medications)

−11

Tsioufis

4.5 ± 0.6

17(100)

Patients with resistant hypertension

−19*

Kiuchi

4.7 ± 1.2

45(100)

Resistant hypertensive CKD patients

−50.8*

Mahfound

4.6 ± 1.6

46(84)

Patients with an office systolic blood pressure (SBP) above goal (≥140 mmHg) or mean ambulatory 24-h SBP 0.135 mmHg despite the use of ≥3 antihypertensive agents of different classes, including a diuretic at maximum or highest tolerated doses

−22*

Brandt

4.7 ± 0.5

46(100)

Patients had an office BP of 160 mm Hg (150 mm Hg for type 2 diabetes patients) or more, despite treatment with at least 3 antihypertensive drugs (including a diuretic), with no changes in medication for a minimum of 3 months before enrollment.

−27.8*